- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07810647
Effectiveness of Shared Decision Making(SDM)on Patients With Poor Control Type 2 Diabetes (SDM)
Studieöversikt
Detaljerad beskrivning
Background Diabetes and hyperglycemia not only increase the risk of complications of cardiovascular disease and lead to a situation involving exposure to danger of death. Meanwhile, the patient's self-management is one of the key factors affecting the quality control of blood sugar. Thereby, Shared Decision Making (SDM) is a patient-centered medical implementation method that healthcare professionals and patients jointly participate in treatment decision-making to reach a consensus, which can stimulate the health care ability of participants to achieve treatment goals.
Purpose: This research aims to implement the SDM model based on self-efficacy theory through individualized decision-making to strengthen the behavioral motivation of diabetic patients and finally, to improve the patient's health promotion behavior and the effectiveness of blood sugar control.
Method: Study Type: Interventional Actual Enrollment:76 participants Allocation:Randomized Intervention Model:Parallel Assignment Masking:Single(Participant)
Expected results:
It is hoped that the implementation of SDM model will be used to strengthen the behavioral motivation of diabetic patients through individualized decision-making, and to confirm whether it can effectively improve the patient's health behavior and the effectiveness of disease control.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Taiwan
-
Tainan, Taiwan, Taiwan, 709204
- An Nan Hospition-China Medical University
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Aged>20y/o
- Diagnosed by a physician as type 2 diabetes
- The Diabetes Participated in the Diabetes Shared Care Network
- Glycosylated hemoglobin (A1C)> 7.5%
- Can communicate in Chinese or Taiwanese.
Exclusion Criteria:
- People with mental or cognitive impairment who cannot communicate
- Health Literacy score lower than 6 points
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Inget ingripande: Control group:as usual care
The control group received as usual care.
|
|
|
Experimentell: Experimental group:The intervention of SDM
The experimental group received the intervention of SDM 3 times for 3 months,
|
The experimental group received the intervention of SDM 3times/month for 3months, then follow the health promotion behavior compliance by phone once a month.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Diabetes self-efficacy scale
Tidsram: Pre-test (baseline)
|
assesses the confidence of diabetes patients in their ability to manage their diet, blood sugar, and physical exercise
|
Pre-test (baseline)
|
|
Diabetes self-efficacy scale
Tidsram: 1 months after intervnetion
|
assesses the confidence of diabetes patients in their ability to manage their diet, blood sugar, and physical exercise
|
1 months after intervnetion
|
|
Diabetes self-efficacy scale
Tidsram: 3 months after intervnetion
|
assesses the confidence of diabetes patients in their ability to manage their diet, blood sugar, and physical exercise
|
3 months after intervnetion
|
|
Diabetes health literacy scale
Tidsram: Pre-test (baseline)
|
A disease-specific scale to measure functional, communicative and critical health literacy in primary care
|
Pre-test (baseline)
|
|
Diabetes health literacy scale
Tidsram: 3 months after intervnetion
|
A disease-specific scale to measure functional, communicative and critical health literacy in primary care
|
3 months after intervnetion
|
|
Diabetes health promotion scale
Tidsram: Pre-test (baseline)
|
A self-report study instrument that includes the health profile, and Diabetes Health Promotion Scale
|
Pre-test (baseline)
|
|
Diabetes health promotion scale
Tidsram: 1 months after intervnetion
|
A self-report study instrument that includes the health profile, and Diabetes Health Promotion Scale
|
1 months after intervnetion
|
|
Diabetes health promotion scale
Tidsram: 3 months after intervnetion
|
A self-report study instrument that includes the health profile, and Diabetes Health Promotion Scale
|
3 months after intervnetion
|
|
Hemoglobin A1C (HbA1c) Test
Tidsram: 3 months after intervnetion
|
An HbA1c test shows what the average amount of glucose attached to hemoglobin has been over the past three months.
|
3 months after intervnetion
|
|
Hemoglobin A1C (HbA1c) Test
Tidsram: Pre-test (baseline)
|
An HbA1c test shows what the average amount of glucose attached to hemoglobin has been over the past three months
|
Pre-test (baseline)
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- FooyinU
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .